Curevac

CureVac, acquired by BioNTech, pioneers mRNA therapeutics and vaccines—including COVID‑19, cancer immunotherapies, and urinary‑tract infection vaccines—leveraging proprietary RNA printer technology.

Headquarters: Germany (DEU)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical and Diagnostic Laboratories

Employees: 825
HQ: Tübingen

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
CVAC	Curevac Cap: 1.0B \| P/E: 7.0	EQUITY	NGM	USD	NL0015436031	Active	📈